Debt to Equity Ratio Chart

Historical Debt to Equity Ratio Data

View and export this data back to 2003. Start Trial.
Date Value
August 31, 2026 -0.2781
May 31, 2026 -0.2486
February 28, 2026 -0.2611
November 30, 2025 -0.2277
August 31, 2025 -0.2744
May 31, 2025 -0.2847
February 28, 2025 -0.2938
November 30, 2024 -0.3215
August 31, 2024 -0.3423
May 31, 2024 -0.2576
February 29, 2024 -0.2554
November 30, 2023 -0.2908
August 31, 2023 -0.2865
May 31, 2023 -0.3247
February 28, 2023 -0.3408
November 30, 2022 -0.3227
August 31, 2022 -0.3961
May 31, 2022 -0.3898
February 28, 2022 -1.613
November 30, 2021 -3.512
August 31, 2021 -2.065
May 31, 2021 -3.02
February 28, 2021 -2.453
November 30, 2020 -7.816
August 31, 2020 11.71
Date Value
May 31, 2020 -6.190
February 29, 2020 -0.9409
November 30, 2019 -0.5944
August 31, 2019 -1.328
May 31, 2019 -0.9244
February 28, 2019 -1.232
November 30, 2018 -0.6941
August 31, 2018 -0.2563
May 31, 2018 0.00
February 28, 2018 0.00
November 30, 2017 -0.4216
August 31, 2017 -0.5378
May 31, 2017 -0.9596
February 28, 2017 0.00
November 30, 2016 0.00
August 31, 2016 0.00
May 31, 2016 0.00
February 29, 2016 0.00
November 30, 2015 0.00
August 31, 2015 -0.4455
May 31, 2015 -0.5874
February 28, 2015 -1.486
November 30, 2014 -1.980
August 31, 2014 3.962
May 31, 2014 0.5963

Debt to Equity Ratio Definition

The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.

Read full definition.

Debt to Equity Ratio Range, Past 5 Years

View Debt to Equity Ratio Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Debt to Equity Ratio Benchmarks

View Debt to Equity Ratio Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 0.0565
Alnylam Pharmaceuticals, Inc. 2.206
Anika Therapeutics, Inc. 0.1839
Savara, Inc. 0.2117
Vericel Corp. 0.2556